Announcement of a Limited Competition for the Continuation of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) [U01]

The summary for the Announcement of a Limited Competition for the Continuation of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) [U01] grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Announcement of a Limited Competition for the Continuation of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) [U01]: The NHLBI is requesting competing renewal applications from the 17 institutions with cooperative agreements currently funded as part of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN). These awards resulted from RFA-HL-02-001, Transfusion Medicine/Hemostasis Clinical Research Network (http://grants.nih.gov/grants/guide/rfa-files/RFA-hl-02-001.html). This network provides a unique collaborative structure for clinical studies. The extensive time and processes involved in establishing the collaboration essential for efficient development and implementation of protocols as a network warrants this limited re-competition for one renewal cycle. The experience gained by the current group of investigators in working together, designing protocols suitable for a clinical research network setting, and maintaining high quality follow-up data is considerable. Keeping the group intact for one more grant award cycle will take maximum advantage of this experience. Should the grants be successfully reviewed, the current network will continue for five more years, depending on the availability of funds. After that point, the NHLBI will determine the feasibility of maintaining a clinical research network in transfusion medicine and hemostasis and, if appropriate, the NHLBI will issue an entirely new request for applications as an unlimited competition.